Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D

CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savings to be reinvested to support up to 20 new product launches.

Scroll to Top